Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers
Authors:
- Paweł SurowiakPSPaweł Surowiak
- Verena MaternaVMVerena Materna
- Carsten DenkertCDCarsten Denkert
- Hermann LageHLHermann Lage
- 1 April 2006
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 235 (2) , 272-280
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic responseGynecologic Oncology, 2004
- Cyclooxygenase-2 and Gastrointestinal CancerThe Cancer Journal, 2004
- Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 ExpressionCancer Research, 2004
- Primary ovarian cancer chemotherapy: current standards of careBritish Journal of Cancer, 2003
- Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interferenceOncogene, 2003
- Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?The Lancet Oncology, 2003
- Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinomaCancer, 2003
- Regulation of MDR-1 (P-glycoprotein) by Cyclooxygenase-2Journal of Biological Chemistry, 2002
- Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian CarcinomaThe American Journal of Pathology, 2002
- Expression of Cyclooxygenase-2 in Human Transitional Cell Carcinoma of the Urinary BladderThe American Journal of Pathology, 2001